Requires DOBI to review hormone replacement therapy coverage.
Summary
This bill directs the New Jersey Department of Banking and Insurance (DOBI) to conduct a one-time confidential review of how health insurance carriers are administering hormone replacement therapy (HRT) coverage under the New Jersey Menopause Coverage Act. The review must also assess whether HRT coverage has increased overall since that act took effect. The bill is framed as a monitoring and oversight measure rather than a direct coverage mandate.
To carry out the review, DOBI must examine available data on prior authorization and step therapy exception approvals and denials for HRT coverage, along with any other information the Commissioner of Banking and Insurance determines is relevant and available in the ordinary course of a carrier’s business. DOBI must then report its conclusions to the Legislature six months after the bill’s effective date. The act takes effect immediately and expires once the report is submitted.
Impact
The bill does not itself change benefit mandates or insurance coverage requirements; instead, it supplements the New Jersey Menopause Coverage Act by creating a temporary reporting and oversight obligation for DOBI. It authorizes the department to collect and analyze carrier data related to HRT coverage administration, including prior authorization and step therapy exceptions, and to transmit findings to the Legislature. The practical impact is on DOBI and health insurance carriers, which may need to provide data for the review, and on lawmakers, who would receive information to evaluate whether the earlier menopause coverage law is being implemented as intended.
Sentiment
The available text and context suggest a generally supportive, oversight-oriented approach to the bill. Because there are no committee transcripts or recorded votes provided, there is no documented opposition or debate in the materials supplied. The bill’s structure indicates a neutral fact-finding purpose, aimed at assessing implementation and coverage trends rather than expanding regulation immediately.
Contention
The main potential point of contention is the scope of DOBI’s review and the burden on health insurance carriers to supply data, especially regarding prior authorization and step therapy practices. Another possible issue is whether the bill’s confidential review and limited reporting timeline will produce enough transparency to satisfy lawmakers and advocates seeking accountability for menopause-related coverage. However, no specific opposing arguments or named stakeholders are included in the provided materials.